Neoadjuvant therapy for melanoma : is it ready for prime time? / Helmink, Beth; Wargo, Jennifer A.In: The Lancet Oncology, Vol. 20, No. 7, 07.2019, p. 892-894.
Research output: Contribution to journal › Comment/debate
TY - JOUR
T1 - Neoadjuvant therapy for melanoma
T2 - is it ready for prime time?
AU - Helmink, Beth
AU - Wargo, Jennifer A.
N1 - Funding Information: JAW reports compensation for speaker's bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, MedImmune, and Bristol-Myers Squibb, serves as a consultant or advisory board member for Roche–Genentech, Novartis, AstraZeneca, GlaxoSmithKline, Bristol-Myers Squibb, Merck, Biothera Pharmaceuticals, and Microbiome DX, and also receives research support from GlaxoSmithKline, Roche–Genentech, Bristol-Myers Squibb, and Novartis. BH is supported by the National Institutes of Health T32 CA 009599 and the MD Anderson Cancer Center support grant ( P30 CA016672 ). The authors would like to acknowledge all of those who have helped make these efforts possible, including the executive committee and the entire membership of the International Neoadjuvant Melanoma Consortium, academic and industry partners, funding agencies and regulatory bodies, as well as the patients who participated in these trials.
PY - 2019/7
Y1 - 2019/7
UR - http://www.scopus.com/inward/record.url?scp=85068050201&partnerID=8YFLogxK
U2 - 10.1016/S1470-2045(19)30377-8
DO - 10.1016/S1470-2045(19)30377-8
M3 - Comment/debate
C2 - 31171445
AN - SCOPUS:85068050201
VL - 20
SP - 892
EP - 894
JO - The Lancet Oncology
JF - The Lancet Oncology
SN - 1470-2045
IS - 7